Monacolin

Monacolin: A Comprehensive Reference

1. Identity, Chemical Names, and Natural Source

Monacolins are a group of naturally occurring polyketide compounds produced during the fermentation of rice with certain Monascus fungi. Monacolins are a group of naturally occurring compounds produced by certain fungi in fermented foods, most notably in red yeast rice, which is rice fermented with the mold Monascus purpureus.

The term "monacolin" therefore encompasses an entire family of structurally related molecules. Depending on the conditions of the yeast fermentation and the strain used, several types of monacolins have been identified to date, including compactin, monacolins M, L, J, and X, as well as the subtype monacolin K, which is structurally identical to lovastatin and is consequently used as a marker of product purification.

The most clinically significant member of this family is Monacolin K. Its full chemical identity is well-established: the controversy surrounding it stems from the paradox that monacolin K, produced naturally through the fermentation of traditional red yeast rice, is chemically identical to the cholesterol-lowering drug lovastatin. The inactive lactone prodrug form of monacolin K (lovastatin) and its lipid-lowering active metabolite, monacolin K hydroxy acid, represent the two principal forms of the molecule in biological systems.

Chemical analysis established that lovastatin and monacolin K are identical chemical compounds. The two isolations, documentations, and patent applications occurred months apart. Lovastatin became the patented, prescription drug Mevacor.

The parent organism is Monascus purpureus, commonly called red koji or red yeast, though monacolins can also be produced by certain Aspergillus species under specific fermentation conditions. Red yeast rice is a bright reddish-purple fermented rice that acquires its color from being cultivated with the mold Monascus purpureus, and is referred to as a kōji in Japanese, meaning "grain or bean overgrown with a mold culture," a food preparation tradition going back to ca. 300 BC.

Forms and Preparations

Red yeast rice comes in the forms of food, traditional Chinese medicine, dietary supplements, and other products. In its raw food form, red yeast rice is used as a culinary ingredient, food colorant, and fermentation starter. As a modern supplement, it is typically sold as encapsulated powder of dried, fermented rice, standardized (where permitted by regulation) to a specified monacolin K content.

Red yeast rice contains sugars (25% to 73%, mainly starch), proteins (14% to 31%), water (2% to 7%), fatty acids (1% to 5%), pigments, sterols, and isoflavones. During the fermentation process, the yeast enriches the rice with polyketides that have clinically detectable cholesterol-lowering action — the monacolins. The monacolin concentration in RYR dietary supplements is typically up to 1.9%.

In addition to rice starch, protein, fiber, sterols, and fatty acids, red yeast rice contains numerous active constituents, including monacolin K, dihydromonacolin, and monacolin I to VI. Notably, traditional red yeast rice may contain only trace amounts of monacolin K, and some commercial red yeast rice products contain very little or no detectable monacolin K.

2. Traditional and Historical Use

Red yeast rice has been used in China for over a thousand years as both a food colorant and medicinal ingredient, and it appears across a long lineage of Chinese medical and dietary literature, described as helping with digestion and blood circulation.

In addition to its culinary use, red yeast rice is also used in Chinese herbology and Traditional Chinese Medicine, possibly during the Tang dynasty around AD 800. Red yeast rice is described in the Chinese pharmacopoeia Ben Cao Gang Mu by Li Shizhen.

Its therapeutic benefits as both a promoter of blood circulation and a digestive stimulant were first noted in the traditional Chinese pharmacopoeia Ben Cao Gang Mu-Dan Shi Bu Yi during the Ming Dynasty (1368–1644). Practitioners of Traditional Chinese Medicine used red yeast rice to treat abdominal pain due to stagnant blood and dysentery, as well as external and internal trauma. In addition to its therapeutic applications, red yeast rice was used for centuries as a flavor enhancer, a food preservative, and a base for a Taiwanese alcoholic rice-wine beverage.

Red yeast rice has been used to produce alcoholic beverages and various fermented foods in China and Korea since ancient times; it has also been used to produce tofuyo (Okinawan-style fermented tofu) in Japan since the 18th century.

For centuries, hong qu (red yeast rice) has been used in China as both a food and herbal medicine. It has also been used as a coloring agent to prepare fish, fish sauce, fish paste, rice wine, and red soybean curd.

It is important to emphasize that none of the traditional uses described above were based on knowledge of monacolins as distinct molecular entities. The cholesterol-lowering property now attributed specifically to monacolin K was not part of any traditional indication; it was only identified in the late 20th century through modern scientific investigation.

Discovery of Monacolins as Distinct Compounds

In the 1970s, Japanese microbiologist Akira Endo identified cholesterol-lowering compounds produced by fungi, including monacolin K–related substances. His research established that these compounds inhibit the enzyme HMG-CoA reductase, a key regulatory step in cholesterol biosynthesis.

In the late 1970s, researchers in the United States and Japan were isolating lovastatin from Aspergillus and monacolins from Monascus, the same fungus used to make red yeast rice when cultured under carefully controlled conditions. Chemical analysis soon showed that lovastatin and monacolin K are identical chemical compounds, and the two isolations, documentations, and patent applications occurred months apart. In the late 1990s, red yeast rice was introduced and used in the United States as a dietary supplement to promote healthy cholesterol levels.

3. Key Constituents and Active Compounds

While red yeast rice contains many bioactive constituents including sterols, isoflavones, and pigments, the monacolins — and particularly monacolin K — are considered the primary cholesterol-lowering agents.

Monacolin K (Lovastatin)

Monacolin K was first isolated by Professor Akira Endo and found to be structurally identical to lovastatin. Its primary mechanism of action is to inhibit 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-controlling enzyme of the cholesterol synthesis pathway.

The main cholesterol-lowering agents in red yeast rice are monacolins, particularly monacolin K, which is a weak reversible inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, whose daily consumption (up to 10 mg/day) reduces LDL-C plasma levels up to 34% within 6–8 weeks when compared to placebo.

Other Monacolins

Compactin is likely to be only half as effective with respect to HMG-CoA reductase inhibition as monacolin K. Therefore, the bioavailability of the individual monacolins is difficult to determine in the presence of monacolin K, and it may be useful to specify a total monacolin content in the form of "monacolin equivalents."

Monacolin L has also attracted attention in preclinical research. A statin, monacolin L, and a red pigment, rubropunctatin, from red yeast rice exhibited very strong cancer cell proliferation inhibitory effects; monacolin L and rubropunctatin exerted their anticancer activity via telomerase inhibitory effects. However, these findings are limited to in vitro cell culture systems and have not been confirmed in human clinical trials.

Mechanism of Action of Monacolin K

The main cholesterol-lowering mechanism of action of red yeast rice is due to the ability of monacolins to reversibly inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol synthesis pathway, the same enzyme inhibited in a stronger way by statins.

Lovastatin, like other statin drugs, helps slow the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of arteries and block blood flow to the heart, brain, and other parts of the body.

Beyond direct HMG-CoA reductase inhibition, monacolin K is known to exhibit pleiotropic effects. The reduction in LDL-C is often accompanied by lower levels of plasma apolipoprotein B, total cholesterol, matrix metalloproteinases 2 and 9, high-sensitivity C-reactive protein, non-high-density lipoprotein cholesterol, and blood pressure.

Like other statins, monacolin K improves endothelial function and has an anti-inflammatory effect, as measured by the plasma level of C-reactive protein. Monacolin K demonstrates a variety of biological activities, including anti-inflammatory, antitumor, anticancer, and neuroprotective effects, highlighting its potential in managing metabolic syndrome. These additional biological activities remain mostly characterized in pre-clinical or preliminary clinical studies (see below).

Pharmacokinetics: Monacolin K vs. Lovastatin

Although monacolin K and lovastatin have the same structure, their pharmacokinetic profiles and bioavailability are different. Lovastatin is administered as a single active ingredient with 31% bioavailability in humans, whereas monacolin K is only one of several red yeast rice components that can change the pharmacokinetic profile of lovastatin.

Overall, in vitro simulated digestion and computational pharmacokinetic predictions suggested that intestinal bioaccessibility is one of the most important features that determines statin bioavailability, and that the red yeast rice phytocomplex could act in a synergistic way to improve monacolin K absorption.

The pharmacokinetics of monacolin K are characterized by a relatively short half-life, a limited intestinal absorption (improved by a full stomach), and metabolism by cytochrome P450. Due to the involvement of the CYP3A4 isoform in its metabolism, interactions with drugs or food ingredients that are inhibitors of this enzyme have been described, leading to increased plasma levels of statins and possible increased risk of toxic effects.

4. Scientific Evidence by Area of Use

4.1 Lipid-Lowering Effects (Hypercholesterolemia)

This is by far the most extensively studied application of monacolin K and the area where the strongest clinical evidence exists.

Mechanism: The primary mechanism of action of monacolin K is inhibition of the key enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, involved in cholesterol synthesis.

Systematic review and meta-analysis evidence: Monacolin K is the major active component in red yeast rice, which is structurally identical to lovastatin and has the most powerful effect in terms of reducing blood cholesterol levels. A systematic review aimed to examine the effect and safety of different doses of monacolin K on blood cholesterol levels. Twelve randomized controlled trials were eligible for inclusion in this analysis, including 769 participants over 18 years old. Eleven out of 12 studies were assessed with high methodological quality.

A 2026 meta-analysis of 10 trials involving 712 patients suggested a significant reduction in LDL-C (weighted mean difference: −34.292 mg/dL; 95% CI: −41.458, −27.126; p < 0.001) and total cholesterol after monacolin K supplementation (WMD: −33.818; 95% CI: −41.630, −26.006; p < 0.001). Furthermore, meta-analysis of 9 trials involving 634 patients suggested a significant elevation in HDL-C (WMD: 2.295; 95% CI: 1.105, 3.484; p < 0.001) and reduction in triglycerides (WMD: −8.659; 95% CI: −17.035, −0.284; p = 0.043) after monacolin K supplementation.

Considering six clinical trials where red yeast rice was the only treatment used to reduce hypercholesterolaemia, changes in total cholesterolaemia and LDL-cholesterolaemia were dose-dependent. The lowest intake of monacolin K effective in reducing total cholesterolaemia (−11.2%) and LDL-cholesterolaemia (−14.8%) was 3 mg/day.

Red yeast rice supplementation reduces LDL-C levels by approximately 15–34% versus placebo, with a similar effect to low-dose, first-generation statins in subjects with mild-to-moderate dyslipidemia.

Specific RCT example (low-dose): A randomized, double-blind, placebo-controlled intervention demonstrated that a low daily dose of 3 mg monacolin K from red yeast rice reduces the concentration of LDL-C, a risk factor for cardiovascular diseases. Previous studies had demonstrated a cholesterol-lowering effect of red yeast rice supplements that contained 5 to 10 mg of monacolin K.

EFSA health claim (2011): In 2011, the European Food Safety Authority (EFSA) issued a key scientific opinion that there was a clear cause-and-effect relationship between consuming monacolin K from red yeast rice and maintaining normal LDL cholesterol levels. EFSA specifically found that a daily intake of 10 mg of monacolin K was effective, leading the European Commission to authorize a health claim for monacolin K from red yeast rice in 2012.

Evidence strength: The lipid-lowering evidence is the strongest of all monacolin K applications — supported by multiple well-conducted RCTs and meta-analyses, and backed by a regulatory health claim from EFSA (since restricted on safety grounds, see Section 6). The consistency of effect across trials and populations is high.

4.2 Cardiovascular Event Reduction (Secondary Prevention)

The most significant hard-endpoint trial involving a monacolin K-containing preparation is the China Coronary Secondary Prevention Study (CCSPS).

This multicenter study was conducted to determine the effects of Xuezhikang (XZK), a partially purified extract of red yeast rice, on lipoprotein and cardiovascular endpoints in Chinese patients who experienced a previous myocardial infarction. Nearly 5,000 of these patients with average LDL-cholesterol levels at baseline were randomly assigned either to placebo or to XZK daily for an average of 4.5 years. The primary endpoint was a major coronary event that included nonfatal myocardial infarction and death from coronary heart disease. Frequencies of the primary endpoint were 10.4% in the placebo group and 5.7% in the XZK-treated group, with absolute and relative decreases of 4.7% and 45%, respectively.

The study confirmed the reduction of LDL cholesterol by about 20%, and documented, during follow-up, a reduction of total cardiovascular events by 37%, and coronary-related deaths by 31%. Overall mortality was also lower in treated patients (−32%).

Red yeast rice has also demonstrated beneficial reductions of up to 45% versus placebo in the risk of atherosclerotic cardiovascular disease events in secondary prevention studies.

Evidence strength: The CCSPS is a large, well-designed randomized trial with hard clinical endpoints and is the strongest evidence base for cardiovascular event reduction. An important limitation is that the preparation used (Xuezhikang) is a complex extract whose active monacolins are not precisely quantified. Certain nutraceuticals, mainly containing red yeast rice, might be considered as an alternative therapy to statins in patients with dyslipidemia, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment.

4.3 Vascular and Endothelial Function

The red yeast rice lipid-lowering effect is associated with significant improvements in pulse wave velocity and endothelial function, which are validated and reliable biomarker tools able to detect vascular aging. These findings are based on validated surrogate marker studies rather than hard cardiovascular endpoint trials and should be interpreted accordingly.

4.4 Blood Pressure

The reduction in LDL-C with red yeast rice is often accompanied by lower levels of plasma apolipoprotein B, total cholesterol, matrix metalloproteinases 2 and 9, high-sensitivity C-reactive protein, non-high-density lipoprotein cholesterol, and blood pressure. Blood pressure effects are generally reported as secondary outcomes in lipid trials rather than as primary endpoints, and should be considered preliminary evidence of moderate strength.

4.5 Metabolic Syndrome and Blood Glucose

In patients with metabolic syndrome, nutraceutical supplementation containing monacolin K was safe, well tolerated, and effective in improving clinic blood pressure, as well as lipid and glucose profiles. This was a secondary-outcome finding rather than the primary purpose of the study.

In an open, uncontrolled pilot study of 24 patients with non-alcoholic fatty liver disease (NAFLD) and mild hypercholesterolemia treated with 10 mg/day of monacolin K for 26 weeks, monacolin K significantly reduced plasma alanine aminotransferase, cholesterol, triglycerides, and the homeostatic model assessment (HOMA) index, indicating improved insulin sensitivity. This pilot study suggests possible benefits of monacolin K use in NAFLD patients that could be linked to a reduction in oxidative stress, but this hypothesis should be further investigated in future studies.

Evidence strength: Evidence for effects on blood glucose and metabolic syndrome is preliminary, limited to small studies with mixed designs, and often as secondary endpoints. No large, well-powered RCTs specifically targeting these outcomes have been published.

4.6 Anti-inflammatory and Antioxidant Effects

In the NAFLD pilot study, no significant changes were found in body fat mass and visceral fat or in liver elastography, while the fatty liver index was significantly decreased. Plasma levels of both malondialdehyde and oxidized glutathione were markedly reduced by monacolin K treatment, suggesting a reduction in oxidative stress and lipid peroxidation.

Monacolin K has anti-inflammatory effects and anti-cancer mechanisms, though the clinical significance of these effects relative to its established lipid-lowering activity is less well documented.

Evidence strength: Anti-inflammatory and antioxidant effects in humans remain supported only by surrogate biomarkers (e.g., hsCRP, malondialdehyde) as secondary outcomes in small trials. No clinical trials have been powered or designed to test these effects as primary endpoints in humans.

4.7 Anticancer and Neuroprotective Effects

In terms of neuroprotection, monacolin K and other statins have demonstrated significant efficacy in the prevention and treatment of neurological disorders such as Parkinson's disease, in improvement in memory, schizophrenia, depression, and type I neurofibromatosis. However, these findings largely pertain to statin-class effects rather than to monacolin K supplementation specifically from dietary sources.

Monacolin K represents a promising bioactive compound with diverse health benefits, particularly in regulating cholesterol levels and preventing cardiovascular disease. Future studies should focus on determining the optimal dosage, long-term efficacy, and safety of monacolin K, facilitating its integration into standard treatment regimens for metabolic abnormality and related conditions.

Evidence strength: Anticancer and neuroprotective effects have been demonstrated in vitro and in some animal models. Human clinical evidence directly attributable to dietary monacolin K supplementation is absent. These remain areas of exploratory research only.

5. Body Systems and Health Areas

• Cardiovascular system: Primary area of use and strongest evidence base. Modulates LDL-C, HDL-C, triglycerides, apolipoprotein B, and endothelial function. Large RCT data for secondary prevention of major cardiovascular events.
• Hepatic system: Preliminary evidence of benefit in NAFLD via reduction of liver enzymes and oxidative stress markers. Also a site of potential adverse effects (liver enzyme elevation) at higher doses.
• Musculoskeletal system: Adverse effect target — myalgia and, rarely, rhabdomyolysis, sharing the same mechanism as statin-associated myopathy.
• Metabolic/endocrine: Preliminary evidence suggesting improvement in insulin sensitivity and glucose profile in small, mostly uncontrolled studies.
• Neurological system: Preclinical and statin-class evidence only; no clinical RCT data specific to monacolin K supplementation.
• Renal system: Potential adverse effect target, particularly when red yeast rice preparations contain the mycotoxin citrinin.

6. Dosage Forms and Doses Reported in Studies

Monacolin K from red yeast rice is consumed primarily in encapsulated powder form. The variability in monacolin K content across commercial products is a well-documented problem. A study published in 2010 investigated a series of fermented red rice products purchased on the Internet which were tested for their content of monacolin K (all declared a content of 10 mg). The study revealed a wide range of active compound, varying by a factor of 100 (from 0.1 to 10.5 mg); the same analysis revealed the presence of citrinin, a nephrotoxic alkaloid, in some of the preparations.

The following doses have been used or reported in published studies and regulatory assessments:

• 3 mg/day: A low daily dose of 3 mg monacolin K from red yeast rice reduces the concentration of LDL-C. This is also the threshold dose at which EFSA identified severe adverse reactions in individual case reports.
• 3–10 mg/day: A daily consumption of between 3 and 10 mg monacolin K has only minimal associated risks; mild myalgias are seen only in the frailest patients — those who also cannot tolerate minimal dosages of statin.
• 10 mg/day: Daily consumption of up to 10 mg/day reduces LDL-C plasma levels up to 34% within 6–8 weeks when compared to placebo. Some crossover studies enrolled patients who received dietary supplements both containing monacolin K 10 mg for 8 weeks each, separated by a 4-week washout period.
• 10 mg/day in NAFLD: A prospective, uncontrolled, open study treated 24 patients with NAFLD and mild hypercholesterolemia with 10 mg/day of monacolin K, measuring outcomes at baseline and after 26 weeks.
• Xuezhikang in CCSPS (~10–12.8 mg monacolin K equivalent/day): The CCSPS trial enrolled 4,870 Chinese patients with prior myocardial infarction and followed them for 4.5 years. Participants received Xuezhikang (600 mg three times daily, approximately 10–12.8 mg total lovastatin-equivalent) or placebo.
• Regulatory limit in EU (post-2022): The European Commission declared in 2022 that red yeast rice products must contain less than 3 mg of monacolins for daily consumption.

7. Safety Considerations and Drug Interactions

7.1 Adverse Effect Profile

Red yeast rice products that contain significant amounts of monacolin K can have the same potential side effects as statin drugs, including muscle, kidney, and liver damage. They may also cause digestive problems such as diarrhea, nausea, and stomach pain.

According to four clinical studies and EMA Pharmacovigilance data, the most frequent adverse effects to lovastatin have as a target the following organs/systems, in decreasing order of frequency: musculoskeletal and connective tissue including rhabdomyolysis (53.4% of EMA reports), nervous system (20.3%), gastrointestinal tract (14.9%), kidney (11.3%), liver (10%), skin and subcutaneous tissue (8.9%), and other minor targets.

Notably, observed adverse event rates in pharmacovigilance databases for red yeast rice supplements appear numerically low relative to the total caseload. In terms of all musculoskeletal disorders from September 2013 to 30 September 2023, 363,879 cases were reported in the FDA Adverse Event Reporting System (FAERS), with the number of cases related to red yeast rice consumption being very small and accounting for 0.008% of cases. During the same period, 27,032 cases of hepatobiliary disorders were reported, with cases attributable to red yeast rice use accounting for 0.01% of all cases. A low rate of muscle symptoms and liver dysfunction attributable to red yeast rice use was also observed in the CAERS database. This profile mirrors that of meta-analyses of randomised clinical trials of red yeast rice, in which use was not associated with either liver dysfunction or muscular adverse symptoms.

7.2 Regulatory Safety Assessments

The EFSA Panel considered that the available information on adverse effects reported in humans was sufficient to conclude that monacolins from red yeast rice when used as food supplements were of significant safety concern at the use level of 10 mg/day. The Panel further considered that individual cases of severe adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. The Panel concluded that exposure to monacolin K from red yeast rice could lead to severe adverse effects on the musculoskeletal system, including rhabdomyolysis, and on the liver.

The EFSA scientific opinion concluded that consuming monacolin K at doses as low as 3 mg per day could lead to severe adverse effects, including rhabdomyolysis (a serious muscle condition) and liver damage. The EFSA panel could not identify a guaranteed safe dietary level of monacolins from red yeast rice products.

In the United States, in 1998 the U.S. Food and Drug Administration (FDA) initiated action to ban a dietary supplement containing red yeast rice extract, stating that red yeast rice products containing monacolin K are identical to a prescription drug, and thus subject to regulation as a drug.

Globally, monacolin K is treated as a food in China, a functional supplement in Japan, a regulated medicine in Australia, an unapproved drug in the United States, and an up-until-recently permitted supplement in Europe.

7.3 Citrinin Contamination

The literature points to a lack of standardization of monacolin content and also the detection of the mycotoxin citrinin in some products. Citrinin is described as nephrotoxic and teratogenic and resulted in the development of renal tumors in rats. EFSA's opinion also made reference to the EFSA CONTAM Panel's opinion on citrinin, a nephrotoxic mycotoxin which can be produced by some strains of Monascus purpureus. In 2019, the European Commission introduced a regulatory limit on citrinin, the toxic mycotoxin that can occur in fermented products like red yeast rice. Citrinin targets the kidneys where it can disrupt normal cellular function, trigger oxidative stress, and damage renal tubule cells responsible for filtering waste from the blood.

7.4 Drug Interactions

Monacolin K is metabolized, like lovastatin, by the isoenzyme CYP3A4 of cytochrome P450 (responsible for the metabolism of about 50% of drugs used in humans); hence, the theoretical possibility of drug interaction is not negligible, despite the low dose of the compound.

Monacolin K has potential drug interactions with other lipid-lowering medications, CYP3A4 inhibitors, and drugs affecting muscle metabolism.

Red yeast rice has varying amounts of monacolin K similar to lovastatin. Products are not standardized and no red yeast rice product should be given to a patient taking a prescription statin. Concomitant use with prescription statins risks effective double-dosing and increased risk of adverse effects.

Taking red yeast rice products and statins at the same time can easily lead to overdosing and side effects. Lovastatin should also be used with caution in patients who consume significant amounts of alcohol and/or have a history of liver disease.

7.5 Contraindications in Pregnancy and Lactation

One ingredient in red yeast rice is monacolin K, also known as mevinolin or lovastatin. Based on theoretical considerations and small case studies, statins are potential teratogens. Use should be avoided during pregnancy and lactation. CNS and limb defects have been reported in newborns exposed to statins in utero.

Special warnings and precautions for use in the Summary of Product Characteristics for lovastatin-containing medicinal products refer to the risk of myopathy/rhabdomyolysis, which is increased by concomitant use of lovastatin with certain other medicinal products, and discourage use of lovastatin by pregnant and lactating women.

7.6 Long-Term Safety

Monacolin K has many pleiotropic effects including anti-inflammatory and anti-cancer mechanisms. It should be emphasized that the long-term safety of regular use of these preparations has not been fully documented.

Available information on potential adverse effects indicates that individuals taking monacolin K at a dose of 10 mg/day may experience muscle symptoms or liver dysfunction and/or severe acute hepatitis; serious adverse events have been reported even at a dose of 3 mg/day.

References

• Red yeast rice with monacolin K for the improvement of hyperlipidemia: A narrative review — PubMed (2025)
• Red Yeast Rice for Hypercholesterolemia — PMC / JACC Focus Seminar (2021)
• Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar — Journal of the American College of Cardiology (2021)
• Scientific Opinion on the Safety of Monacolins in Red Yeast Rice — EFSA Journal (2018)
• Red Yeast Rice — NIH National Center for Complementary and Integrative Health (NCCIH)
• Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials — Endocrinology, Diabetes & Metabolism (2026)
• Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention — PubMed (2016)
• Monacolin K supplementation in patients with hypercholesterolemia: A systematic review of clinical trials — ScienceDirect (2024)
• Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction (CCSPS) — PubMed (2008)
• Scientific opinion on the safety of monacolins in red yeast rice — PMC (2020)
• A Review of Red Yeast Rice, a Traditional Fermented Food in Japan and East Asia — PMC (2021)
• Effects of Monacolin K in Nondiabetic Patients with NAFLD: A Pilot Study — PMC (2023)
• The Impact of Red Yeast Rice Extract Use on the Occurrence of Muscle Symptoms and Liver Dysfunction: An Update from the Adverse Event Reporting Systems — PMC (2024)
• LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial — PMC (2018)
• Telomerase Inhibitory Effects of Red Pigment Rubropunctatin and Statin Monacolin L Isolated from Red Yeast Rice — PMC (2017)
• Primary prevention and hypercholesterolaemia: 'Doc, please, give me the natural statin' — European Heart Journal Supplements (2019)
• The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion — ScienceDirect (2019)
• A clinician's guide to statin drug-drug interactions — Journal of Clinical Lipidology (2014)
• Investigating the biosynthesis pathways and hypolipidemic mechanisms of monacolin K in Monascus species — PubMed (2025)
• Mini-review: medication safety of red yeast rice products — PMC (2019)
• An overview of the bioactivity of monacolin K / lovastatin — ScienceDirect (2019)
• How monacolins from red yeast rice triggered a global regulatory crisis — NutraIngredients (2026)
• EFSA declares monacolins from red yeast rice unsafe at any dose — NutraIngredients (2025)
• Red yeast rice — Wikipedia
• Monacolin K as a Natural Alternative for Synthetic Statins — Quality in Sport (2025)
• Red Yeast Rice or Lovastatin? A Comparative Evaluation of Safety and Efficacy Through a Multifaceted Approach — PMC (2025)
• Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review — PMC (2023)
• Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial — PMC (2023)
• Effects of low-dose monacolin K on the circulating proteome in individuals with suboptimal cholesterolaemia: A randomised clinical trial — medRxiv (2024)